Shareholders Equity: The sum of preferred and common equity items.
Myriad Genetics, Inc. (MYGN) had Shareholders Equity of $368.00M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$209.80M |
|
$-7.90M |
|
$63.00M |
|
$146.80M |
|
$215.50M |
|
$-5.70M |
|
$-3.20M |
|
$-8.90M |
|
$-8.90M |
|
$-7.90M |
|
$-7.90M |
|
$-7.90M |
|
$-7.90M |
|
$-5.70M |
|
$9.60M |
|
92.60M |
|
92.60M |
|
$-0.09 |
|
$-0.09 |
|
| Balance Sheet Financials | |
$332.60M |
|
$114.00M |
|
$374.00M |
|
$706.60M |
|
$133.80M |
|
$119.90M |
|
$204.80M |
|
$338.60M |
|
$368.00M |
|
$163.00M |
|
|
Shareholders Equity |
$368.00M |
93.50M |
|
| Cash Flow Statement Financials | |
$1.80M |
|
$-27.40M |
|
$64.20M |
|
$111.90M |
|
$151.30M |
|
$39.40M |
|
$35.20M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
2.49 |
|
-- |
|
-- |
|
0.25 |
|
0.33 |
|
69.97% |
|
-2.72% |
|
-2.72% |
|
-- |
|
-4.24% |
|
-3.77% |
|
$-13.80M |
|
-- |
|
-- |
|
-- |
|
0.30 |
|
2.06 |
|
1.82 |
|
49.46 |
|
-2.15% |
|
-4.85% |
|
-1.12% |
|
-1.62% |
|
$3.94 |
|
$-0.15 |
|
$0.02 |
|